Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Milan Italy (1939)

Organization Overview

First Clinical Trial
2017
NCT03359538
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ASST Grande Ospedale Metropolitano Niguarda | Azienda Ospedaliera Niguarda Cà Granda | Fondazione IRCCS "Cà Granda" Ospedale Maggiore Policlinico | Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico de Milano | Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy | Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano | Grande ospedale metropolitano Niguarda

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Microsatellite Instability (Phase 2)

Motor Neuron Disease (Phase 2)

Pneumonia (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 15